Company: WHWK
Filing Date: 2025-03-31
Form Type: S-3
Source: 0001193125-25-068942
Chunk: 20

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-31
Form: S-3
Chunk 20
---
 and Ulys, controls Siren and        
 Ulys and, accordingly, may be deemed to beneficially own the shares that Siren and Ulys may be deemed to beneficially own. The principal business address for each of the entities and individuals above is 750 Lexington Avenue, 30th Floor, New York, 
 NY 10022.                                                                                                                                                                                                                                               |

| 9. | Consists of 2,082,000 shares of common stock purchased in the Private Placement by Kalehua Capital Partners LP                                                               
 (“Kalehua Capital”). Kalehua Capital Management LLC (“Kalehua Management”) is the managing partner of Kalehua Capital. Tai-Li Chang has voting and investment authority over 
 all of the shares beneficially owned by each of Kalehua Capital and Kalehua Management. The principal address of Kalehua Capital is 3819 Maple Avenue, Dallas, Texas 75219.  |

| 10. | Consists of (i) 1,666,000 shares of common stock purchased in the Private Placement by KVP Capital, LP                                                                                                                                         
 (“KVP Capital”) and (ii) 499,997 shares of common stock held indirectly by KVP Capital. KVP Capital Advisors, LP is the manager of KVP Capital and KVP Capital GP, LLC is the general partner of KVP Capital. Caley Castelein, M.D., a         
 director of our Company, and Andrew Jensen are the managing members of KVP Capital GP, LLC. Dr. Castelein and Mr. Jensen each disclaims beneficial ownership of the shares held by KVP Capital, except to the extent of his pecuniary interest 
 therein. The principal business address for each of the entities and individuals above is 4 Embarcadero, Suite 2100, CA 94111.                                                                                                                 |

| 11. | Consists of (i) 962,790 shares of common stock purchased in the Private Placement by Acuta Capital Fund, L.P.                                                                                                                                        
 (“Acuta Capital”); (ii) 598,210 shares of common stock purchased in the Private Placement by Acuta Opportunity Fund, L.P. (“Acuta Opportunity Fund”); (iii) 1,572,698 shares previously held by Acuta Capital; and (iv)                              
 276,704 shares previously held by Acuta Opportunity Fund. Acuta Capital Partners, LLC (“Acuta Partners”) is a general partner of each of Acuta Capital and Acuta Opportunity Fund. Anupam Dal